

2013 Current Fiscal Year Report: Veterinary Medicine Advisory Committee

Report Run Date: 04/26/2024 02:22:27 AM

1. Department or Agency

Department of Health and Human
Services

2. Fiscal Year

2013

3. Committee or Subcommittee

Veterinary Medicine Advisory
Committee

**3b. GSA Committee
No.**

1042

4. Is this New During Fiscal Year? **5. Current Charter** **6. Expected Renewal Date** **7. Expected Term Date**

No 04/24/2012 04/24/2014

8a. Was Terminated During Fiscal Year? **8b. Specific Termination Authority**

Yes

**8c. Actual
Term Date**

09/24/2013

9. Agency Recommendation for Next Fiscal Year

Continue

10a. Legislation Req to Terminate?

No

10b. Legislation Pending?

Not Applicable

11. Establishment Authority Authorized by Law

12. Specific Establishment Authority

21 U.S.C. 394

13. Effective Date

11/28/1990

14. Committee Type

Continuing

14c. Presidential?

No

15. Description of Committee Scientific Technical Program
Advisory Board

16a. Total Number of Reports

No Reports for
this Fiscal Year

17a. Open 0 **17b. Closed** 0 **17c. Partially Closed** 0 **Other Activities** 0 **17d. Total** 0

Meetings and Dates

No Meetings

| | Current FY | Next FY |
|-------------------------------------------------------------------------------|---------------|-------------|
| 18a(1). Personnel Pmts to Non-Federal Members | \$0.00 | \$0.00 |
| 18a(2). Personnel Pmts to Federal Members | \$0.00 | \$0.00 |
| 18a(3). Personnel Pmts to Federal Staff | \$51,535.00 | \$0.00 |
| 18a(4). Personnel Pmts to Non-Member Consultants | \$0.00 | \$0.00 |
| 18b(1). Travel and Per Diem to Non-Federal Members | \$0.00 | \$0.00 |
| 18b(2). Travel and Per Diem to Federal Members | \$0.00 | \$0.00 |
| 18b(3). Travel and Per Diem to Federal Staff | \$0.00 | \$0.00 |
| 18b(4). Travel and Per Diem to Non-member Consultants | \$0.00 | \$0.00 |
| 18c. Other(rents,user charges, graphics, printing, mail, etc.) | \$12,884.00 | \$50,649.00 |
| 18d. Total | \$64,419.00 | \$50,649.00 |
| 19. Federal Staff Support Years (FTE) | 0.30 | 0.30 |

20a. How does the Committee accomplish its purpose?

The Veterinary Medicine Advisory Committee advises the Commissioner in discharging their responsibilities as they relate to assuring safe and effective drugs, feeds and feed additives, and devices for animal use, and, as required, any other product for which the Food and Drug Administration has regulatory responsibility.

20b. How does the Committee balance its membership?

The Committee consists of a core of 13 voting members including the Chair, who are knowledgeable of the issues related to the Committee's function. Members and the Chair are selected by the Commissioner, or designee, from among authorities knowledgeable in the fields of companion animal medicine, food animal medicine, avian medicine, microbiology, biometrics, toxicology, pathology, pharmacology, animal science, chemistry, public health/epidemiology and minor species/minor use veterinary medicine. One member is technically qualified and identified with consumer interests. The committee may also include one non-voting member who is identified with industry interests.

20c. How frequent and relevant are the Committee Meetings?

The VMAC did not meet during FY2013. The VMAC was terminated September 24, 2013.

20d. Why can't the advice or information this committee provides be obtained elsewhere?

Members of the committee are drawn from academia, research, and/or clinical practice. Their advice and input lends credibility to regulatory decisions and helps those decisions stand up to intense public scrutiny. The alternate means of obtaining this advice would involve the recruitment of large numbers of scientists on a full-time basis at maximum rates of compensation.

20e. Why is it necessary to close and/or partially closed committee meetings?

There were no closed meetings to report in FY-13. The committee was terminated September 24,

2013.

21. Remarks

No reports required for FY-13. Although this committee did not meet in FY-13, considerable time was devoted to finding out whether or not the committee should be terminated. It was found on September 24, 2013 that the agency no longer needed the committee so it was terminated.

Designated Federal Officer

Aleta M. Sindelar Executive Secretary

| Committee Members | Start | End | Occupation | Member Designation |
|-------------------|------------|------------|---------------------------------------------------------------------------|------------------------------------------|
| Apley, Michael | 03/09/2009 | 10/31/2012 | Associate Professor, Kansas State University | Special Government Employee (SGE) Member |
| Poppenga, Robert | 03/09/2009 | 10/31/2012 | Professor of Clinical Toxicology, University of California @ Davis | Special Government Employee (SGE) Member |
| Senior, David | 03/09/2009 | 10/31/2012 | Associate Dean, Advancement & Strategic Init., Louisiana State University | Special Government Employee (SGE) Member |
| Stromberg, Paul | 03/09/2009 | 10/31/2012 | Professor of Veterinary Pathology, Ohio State University | Special Government Employee (SGE) Member |

Number of Committee Members Listed: 4

Narrative Description

FDA's strategic priorities in responding to the public health challenges of the 21st century are to advance regulatory science and innovation; strengthen the safety and integrity of the global supply chain; strengthen compliance and enforcement activities to support public health; expand efforts to meet the needs of special populations; advance medical countermeasures and emergency preparedness; advance food safety and nutrition; promote public health by advancing the safety and effectiveness of medical

products; establish an effective tobacco regulation, prevention, and control program; and manage for organizational excellence and accountability. The Veterinary Medicine Advisory Committee supports FDA's strategic priorities by advising the Commissioner or designee in discharging responsibilities as they relate to helping to ensure public and animal health by approving safe and effective animal drugs and, as required, any other product for which the Food and Drug Administration has regulatory responsibility.

What are the most significant program outcomes associated with this committee?

Checked if
Applies

| | |
|---------------------------------------------------|-------------------------------------|
| Improvements to health or safety | <input checked="" type="checkbox"/> |
| Trust in government | <input checked="" type="checkbox"/> |
| Major policy changes | <input checked="" type="checkbox"/> |
| Advance in scientific research | <input checked="" type="checkbox"/> |
| Effective grant making | <input type="checkbox"/> |
| Improved service delivery | <input type="checkbox"/> |
| Increased customer satisfaction | <input checked="" type="checkbox"/> |
| Implementation of laws or regulatory requirements | <input checked="" type="checkbox"/> |
| Other | <input type="checkbox"/> |

Outcome Comments

NA

What are the cost savings associated with this committee?

Checked if Applies

| | |
|----------------------------|-------------------------------------|
| None | <input type="checkbox"/> |
| Unable to Determine | <input checked="" type="checkbox"/> |
| Under \$100,000 | <input type="checkbox"/> |
| \$100,000 - \$500,000 | <input type="checkbox"/> |
| \$500,001 - \$1,000,000 | <input type="checkbox"/> |
| \$1,000,001 - \$5,000,000 | <input type="checkbox"/> |
| \$5,000,001 - \$10,000,000 | <input type="checkbox"/> |
| Over \$10,000,000 | <input type="checkbox"/> |
| Cost Savings Other | <input type="checkbox"/> |

Cost Savings Comments

The utilization of the Veterinary Medicine Advisory Committee enables the Agency to obtain required and frequently scarce professional services from medical and scientific experts not otherwise available to the Agency; and to obtain the services of these experts only on an as needed basis rather than on a full time basis. The service of the committee resulted in advice for the improvement of the public health, for which it is difficult to assign a financial value.

What is the approximate Number of recommendations produced by this committee for the life of the committee?

6

Number of Recommendations Comments

The committee met six times since FY2003 to discuss and make a collective recommendation on six separate issues. Each meeting transcript can be found at <http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/VeterinaryMedicineAdvisoryCommittee/Default.aspx?cid=2089>

What is the approximate Percentage of these recommendations that have been or will be Fully implemented by the agency?

80%

% of Recommendations Fully Implemented Comments

The function of an advisory committee is purely advisory in nature. Although the FDA most often accepts the recommendations from its committees, the advice is purely advisory in nature, and therefore, the Agency has the option of not implementing the advice.

What is the approximate Percentage of these recommendations that have been or will be Partially implemented by the agency?

10%

% of Recommendations Partially Implemented Comments

The function of an advisory committee is purely advisory in nature. Although the FDA most often accepts the recommendations from its committees, the advice is purely advisory in nature, and therefore, the Agency has the option of not implementing the advice.

Does the agency provide the committee with feedback regarding actions taken to implement recommendations or advice offered?

Yes ☒ No ☐ Not Applicable ☐

Agency Feedback Comments

It usually does. Product approval issues are first released to the sponsor. When appropriate, information is made available to the public. Actions related to guidance documents or other general matters issues are available publicly when implemented.

What other actions has the agency taken as a result of the committee's advice or recommendation?

Checked if Applies

| | |
|-----------------------------------|-------------------------------------|
| Reorganized Priorities | <input checked="" type="checkbox"/> |
| Reallocated resources | <input type="checkbox"/> |
| Issued new regulation | <input checked="" type="checkbox"/> |
| Proposed legislation | <input type="checkbox"/> |
| Approved grants or other payments | <input type="checkbox"/> |
| Other | <input checked="" type="checkbox"/> |

Action Comments

FDA approves or chooses not to approve an investigational new medical or food product.

Is the Committee engaged in the review of applications for grants?

No

Grant Review Comments

NA

How is access provided to the information for the Committee's documentation?

Checked if Applies

| | |
|---------------------------|-------------------------------------|
| Contact DFO | <input checked="" type="checkbox"/> |
| Online Agency Web Site | <input checked="" type="checkbox"/> |
| Online Committee Web Site | <input checked="" type="checkbox"/> |
| Online GSA FACA Web Site | <input checked="" type="checkbox"/> |
| Publications | <input checked="" type="checkbox"/> |
| Other | <input type="checkbox"/> |

Access Comments

N/A